Abstract: A method of treating a tissue site is provided. The method includes applying a reduced pressure to a tissue site with a reduced pressure source. A source pressure is monitored at the reduced pressure source, and a differential pressure is determined between the source pressure and the desired tissue site pressure. If a blockage is present between the reduced pressure source and the tissue site, the differential pressure is limited to a first maximum differential pressure. If no blockage is present between the reduced pressure source and the tissue site, the differential pressure is limited to a second maximum differential pressure.

Abstract: A digital display air pump includes a rectangular, box-shaped body having a standard AC power cord extending from it, two air supply output ports, and a control and information panel located on its front side with user-operated buttons, a digital display for showing air pressure and alarm codes, a variable air pressure set dial, and status lights. Within the hollow interior of the body is an air compressor, a dual-output electromechanical valve having to two air output tubes, an air pressure sensor, an AC power connection, an internal loudspeaker, and an electronic circuit board controlling the digital display air pump's function. The air supply output ports, an extension of the air tubes within the body, supply air to Intermittent Pneumatic Compression (“IPC”) Therapy device garments through flexible air supply tubes.

Abstract: An electromagnetic valve system for carrying out a compressed air supply to and evacuation from a plurality of air chambers of massage instruments of a pneumatic massage device includes a plurality of first electromagnetic valves each to be connected to a corresponding one of the air chambers; a second electromagnetic valve including a first aperture which communicates with external air; and a plurality of first check valves each within a header in an intermediate location between the second electromagnetic valve and a corresponding one of the air chambers with a connection tube therebetween, the first check valves allowing air to pass from the air chambers toward the second electromagnetic valve only when air pressure on a second electromagnetic valve side is lower than air pressure on an air chamber side.

Abstract: There is disclosed an apparatus for treating a sexual dysfunctional female patient, comprising a stimulation device adapted to stimulate an erectile blood passageway to increase the amount of blood in the female erectile tissue and thereby obtaining engorgement with blood of the female erectile tissue by affecting said erectile blood flow passageway. Moreover there is disclosed a system and an operation method for treating a sexual dysfunctional female patient.

Abstract: A method for reducing an individual's weight through hunger control is provided, wherein predetermined biologically active hunger control points and/or areas on the skin are stimulated utilizing removably attached point stimulation elements (PSEs) (e.g., spherules, etc.), in accordance with a predefined configurable cyclical treatment schedule. Maintenance procedures are also performed by the individual, after a predetermined amount of treatment cycles, to maintain weight reduction benefits gained during the treatments. Additional optional features of the inventive hunger control method include application of at least one of: a dietary plan, a vitamin and chronologically selected herb plan, behavioral modification, and an physical activity protocol.

Abstract: A package includes a container having an open end and a closed end, and a slider slidably mounted within the container. The slider has sidewalls a facing panel and an end wall. The slider has a first end that is closest to the end wall of the container and opposite second end defined by the end wall of the slider. The end wall of the slider is connected to the facing panel of the slider at a first edge thereof, and is connected to a panel of a blister pack carrier at an opposite second edge thereof, the first and second edges of the end wall being connected by side edges of the end wall. The sidewalls of the slider terminate at a position spaced from the end wall of the slider, and a pair of flaps are connected to respective side edges of the end wall of the slider along respective foldlines, each flap being folded toward an end of the sidewall on its respective side of the slider and extending over at least a portion of the distance between the end of the sidewall and the end wall of the slider.

Abstract: A septum is penetrable by a needle for decontamination by physical interaction. The septum can include a peripheral portion, an exterior surface], and an interior surface. A penetration portion extends between the exterior and interior surfaces, is spaced inwardly of the peripheral portion, and is penetrable by the needle or other penetrating element. A flex portion is located between the penetration portion and the peripheral portion. A thicker portion extends between the flex portion and the penetration portion, and defines an increased thickness between the exterior and interior surfaces relative to the flex portion. The flex portion is flexible inwardly relative to the peripheral portion during penetration of the penetration portion by a needle or other penetrating element. The penetration portion physically interacts with and decontaminates the needle when it penetrates the septum. The septum may also reduce or prevent retrograde contamination when the needle is withdrawn.

Abstract: In certain embodiments, a vial adaptor comprises a housing member, a connector configured to couple the adaptor with a vial, and an extractor channel formed in the housing member. The extractor channel is configured to facilitate withdrawal of fluid from the vial when the adaptor is coupled to the vial. In some embodiments, an anti-reflux valve is positioned within the extractor channel. The anti-reflux valve can be configured to impede or obstruct fluid returning to a fluid source after withdrawal of the fluid from the fluid source.

Abstract: Some embodiments disclosed herein related to a device for transferring precise amounts of fluid from at least one source container to a at least one target container. In some embodiments, the fluid is first transferred from the source container (e.g., a vial) through a connector to an intermediate measuring container (e.g., a syringe). In some embodiments air can pass through an air inlet and enter the vial to compensate for the volume of fluid withdrawn from the vial. An air check valve or a bag or a filter can prevent the fluid from escaping through the air inlet. The precisely measured amount of fluid can then be transferred from the intermediate measuring container to the target container (e.g., an IV bag). In some embodiments the connector can include a source check valve and a target check valve to direct fluid first from the source container to the intermediate measuring container and then from the intermediate measuring container to the target container.

Abstract: A drug and fluid dispenser includes a first mechanism for holding and dispensing a fluidized food; a second mechanism for measuring, holding, and dispensing a specified amount of fluid to be taken with a set of medicines at a specified time; a third mechanism for holding and dispensing one or more sets of medicines in a chronological order according to a pre-determined schedule of administration to an individual; a fourth mechanism for granulating a next scheduled set of medicines and mixing the granulated next scheduled set of medicines with the specified amount of fluid at the specified time; a first output mechanism for administering contents of the first mechanism and contents of the fourth mechanism to the individual; and a second output mechanism for rinsing the fourth mechanism subsequent to administration of each of the sets of medicines.

Abstract: A device detects the removal of drugs from a drug blister pack. The device contains a base for receiving the drug blister pack which has a base surface which is configured for contact with the electrically conducting, metal foil that closes the pockets. In the region of the pockets, the base has holes that are configured for the passage of the drugs present in the pocket. In the region of the holes one transmitting coil and at least two receiving coils are each arranged and extend around the respective hole. The receiving coils are associated with each other with respect to the transmitting coil and are arranged such that when the foil resting against the base in the region of the respective hole is undamaged the difference of the voltages induced in the receiving coils by an electric current in the transmitting coil lies below a predetermined threshold value.

Abstract: A heating system for heating neonate nutritional liquid, including a heater and a control module. The heater includes a heating portion having serpentine shaped grooves for receiving a tube. The tube may be a serpentine feeding tube module, having a serpentine tube portion, or a serpentine feeding tube cassette, having a serpentine tube portion covered by a rigidly attached polymeric sheet. The serpentine feeding tube cassette may include a thermocouple to measure the temperature of the warmed nutritional liquid as it exits the cassette.

Abstract: A dental composite composition is disclosed that includes a polymerizable resin, filler particles, and at least one polymerizable stable radical. A variety of polymerizable stable radicals may be employed, including those that have a 2,2,6,6-tetramethylpiperidinyl-1-oxyl moiety. Compositions as described herein exhibit excellent mechanical strength, hardness, and flexural modulus, while also significantly decreasing shrinkage stress caused by polymerization.

Abstract: A multi-functional self-healing dental composite may intrinsically repair the micro-crack and prevent the crack from propagating to catastrophic failure, thus significantly extending the service life of the restorative material. The self-healing dental composite includes a dental resin matrix, fillers, healing powder, and healing liquid containing micro-capsules distributed throughout the matrix. Each of the micro-capsules have a silica she formed by the hydrolysis condensation of TEOS in the presence of an aqueous solution of a healing liquid. The healing liquid includes a homo-polymers(s) and/or copolymer(s) of carboxylic acid(s). The healing powder particles distributed throughout the resin matrix, and include alumina, silica and other elements. The self-healing may be triggered automatically as a result of micro-cracking, induced by thereto/mechanical fatigue. During the self-healing process, antibacterial agents may be released to provide protection of the composites against cariogenic bacteria.

Abstract: A stable, multiphase liquid isotropic cleansing composition is described that contains high levels of Petrolatum and shows a substantial decrease in reflectance compared with isotropic cleansing compositions containing other oils and liquid crystalline compositions with similar levels of oils. The inventive composition has a total of less than 2% by wt. of other oils such as glyceride, mineral and silicone oils, or blends thereof.

Abstract: The invention provides a cosmetic method for, preventing, minimizing and removing wrinkles and providing for smoother and more robust skin surfaces comprising applying a material incorporating water-insoluble copper compounds which release Cu+ ions, Cu++ ions or combinations thereof upon contact with a fluid to a body surface to be treated.

Abstract: A method for removing a radiation-polymerized cosmetic coating from nails comprising applying a solvent system comprising a hydroxyl-containing solvent and a non-hydroxyl-containing solvent to a polymerized nail coating. A two package system comprising a first package comprising polymerizable nail coating composition comprising a (meth)acrylic oligomer, (meth)acrylic monomer, or a mixture of a (meth)acrylic oligomer and a (meth)acrylic monomer, and a photoinitiator, wherein the oligomer or monomer has an acidic or basic ionizable group and a second package comprising a solvent system for removing the polymerizable nail coating composition after it has been applied to a nail and radiation cured, the solvent system comprising a hydroxyl-containing solvent and a non-hydroxyl-containing solvent. A radiation-curable coating composition for human nails is also disclosed.

Abstract: A multi-layer product for improving the look of human skin by the steps of: apply to the skin a first layer that is a skin care composition; and applying to, and on top of, the first layer, a powder layer. The powder layer has from about 10% to about 30%, by weight of the powder layer, of substantially spherical particles selected from the group consisting of coated or uncoated starch, silicone elastomer particles, and combinations thereof. The powder layer is an aqueous based composition that is an oil-in-water emulsion comprising a non-volatile oil present in a concentration level such that the weight ratio of non-volatile oil to particulate material is from about 1:10 to about 3:2. At least one of, or both the first layer and the powder layer have a contrast ratio of less than about 20.

Abstract: The present invention relates to a composition comprising water, at least one surfactant, at least one ester of levulinic acid with a fatty alcohol and a water-soluble salt. Furthermore the present invention relates to the use of at least one ester of levulinic acid with a fatty alcohol for increasing the viscosity of a composition comprising water and at least one surfactant.

Abstract: A personal care composition for hair and skin applications includes an aqueous solution consisting essentially of aggregates of behentrimonium chloride and dihydroxypropyl PEG-5 linoleammonium chloride. The composition forms micro particles or aggregates of behentrimonium chloride that exhibits surprising distributive properties in aqueous solution of a nature beneficial to its application to hair or skin surfaces.

Abstract: The present invention relates to a composition comprising, in a physiologically acceptable aqueous medium, at least one monosaccharide or a polysaccharide containing up to six sugar units, a polyol and a betaine, said composition being free of potassium sorbate. According to a preferred embodiment of the invention, the composition comprises sucrose, 1,3-propanediol and cocoyl betaine, said composition being free of potassium sorbate. The invention also relates to an article comprising such a composition, and also to a cosmetic process for treating keratin materials by applying such a composition and/or such an article.

Abstract: The present invention relates to a cosmetic or pharmaceutical formulation comprising a hyaluronate crosspolymer and one or more of (a) azelaic acid or an ester thereof; (b) one or more of black cumin seed oil, chaulmoogra oil, magnolia bark extract and manuka oil; and (c) resveratrol or a derivative thereof. Uses of the formulation for skin treatments, promoting collagen production and regulating cellular turnover are also described.

Abstract: Disclosed are surfactant compositions containing at least one crosslinked acrylic copolymer. The crosslinked acrylic copolymer is polymerized in the presence of at least two different classes of crosslinking monomers. The crosslinked acrylic copolymers provide desirable rheological, clarity, and aesthetic properties in aqueous surfactant containing compositions.

Abstract: Provided is an oral care composition comprising a phosphate/acrylate co-polymer, zinc and an orally acceptable carrier and methods of using the same.

Abstract: Described herein are whitening compositions comprised of a peroxide component, and an adhesion system, which effectively provide whitening using a remarkably low level of peroxide. Methods of making and using these compositions are also described herein.

Abstract: The present invention relates to a cosmetic composition comprising (a) about 10% to about 20% by weight, based upon the total weight of the composition of a film forming agent; (b) about 1% to about 25% by weight, based upon the total weight of the composition of a particulate material; (c) two or more thickening agents; and (d) water. When applied to the skin, the composition allows for immediate tightening of the skin while decreasing the visibility of fine lines and deep wrinkles.

Abstract: A skin care composition including a cosmetically acceptable oil, from about 0.25% to about 7.0%, based upon the weight of the composition, of a polyglyceryl fatty acid ester surfactant having an hydrophile-lipophile balance value of from about 9 to about 12, and a sunscreen active. The composition is stable.

Abstract: It is an object of the present invention to provide a pharmaceutical composition containing a stable azole-based compound, which is useful as an antifungal agent. According to the present invention, the above-mentioned object can be achieved by adding magnesium hydroxide carbonate, triethylamine, arginine, or another such basic substance to an azole-based compound that is unstable in acids. The above-mentioned pharmaceutical composition is stable enough that the compound will not degrade if the temperature, humidity, or other such conditions should change during production or storage. Also, this composition is useful as a therapeutic agent for deep mycoses because systemic administration is possible by applying it to an oral agent or an injection.

Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.

Abstract: An edible animal medicine container for delivering medicine or other ingestible material, contained therein, to an animal, includes first and second edible housing shells. The first shell includes a first peripheral ledge, surrounding a first central hollow, and a first interlocking feature extending therefrom. The second shell includes a second peripheral ledge, surrounding a second central hollow, and a second interlocking feature extending into, and at least partially defined by, the second peripheral ledge. The second shell is positionable relative to, and connectable to, the first shell to define an interior in which the ingestible material may be disposed. In such connected state the first interlocking feature is seated and frictionally held within the second interlocking feature of the second edible housing shell so as to retain the first and second shells together and thereby retain the ingestible material within the interior until ingested by an animal.

Abstract: Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.

Abstract: Disclosed herein are inventive stable homogenized biomass hetero-colloids, their production and uses. Such biomass hetero-colloids comprise biomass derived solid particle colloid matter and at least 15% (w/w) biomass derived soluble colloid matter. The novel biomass hetero-colloids provide an inventive approach for the application of biologically active compounds. Bio-actives are made available in an innovative form involving low intervention processing and enhancing the biological availability.

Abstract: The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g.

Abstract: Method for the realization Hof a calcium phosphate-based biomaterial in form of granules and/or agglomerates of re-absorbable granules which can be used in the biomedical industry as, e.g., bone fillers, for increasing the bone mass, as a sealing for the internal orthopaedic prosthesis, for releasing drugs and/or medicaments and/or other substances beneficial for the organism. A calcium phosphate-based biomaterial in form of granules and/or aggregates thereof obtained according to such method.

Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.

Abstract: The present invention relates generally to abuse-deterrent formulations containing dextroamphetamine sulfate.

Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.

Abstract: The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

Abstract: A nanostructured biocompatible wafer for placement in the conjunctival cul-de-sac. The wafer contains a tissue-reactive mucoadhesive polymer and a mesh formed of a plurality of hydrophobic polymer fibers. Also provided is a method for treating glaucoma, an ocular surface disorder, or an ocular surface infection using the nanostructured biocompatible wafer. Additionally, an injectable sustained-release formulation for treating an ocular disorder is disclosed. The formulation includes a drug contained within a plurality of microparticles formed of a biodegradable polymer and are coated with a tissue-reactive compound. Further provided is a method for treating an ocular disorder by injecting the microparticulate sustained release formulation.

Abstract: Provided is a transdermal delivery system consisting of a backing layer, a drug-containing matrix layer, and a release layer, wherein the drug-containing matrix layer includes (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a mixture of high molecular weight polyisobutylene having a weight-average molecular weight ranging from 400,000 to 3,000,000 and low molecular weight polyisobutylene having a weight-average molecular weight ranging from 25,000 to 300,000 as an adhesive, and (c) a permeation enhancer in not more than 3% by weight based on the total weight of the drug-containing matrix layer.

Abstract: Compositions contain a therapeutically effective amount of p-anisaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing gylcemia by improving insulin sensitivity, or improving mood, memory or cognition. Methods are provided that include administering such compositions.

Abstract: The present invention relates to a complex comprising acidic sophorolipid and curcumin ((SL(A)+Cur), wherein, curcumin is solubilized and nano-encapsulated in acidic sophorolipid to improve the water solubility, stability and bioavailability of curcumin in order to enhance its therapeutic activity. Further, the invention provides pharmaceutical compositions comprising the present complex and methods to treat cancer in a subject using the said composition.

Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.

Abstract: The invention relates to a novel lipid composition. Further, the invention relates to the use of a lipid composition for the treatment, alleviation and prevention of skin problems.

Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine.

Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

Abstract: Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health.

Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.